pharma · Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors · Atopic Dermatitis · HOTH
Hoth Therapeutics
HotHouse Therapeutics is a pharma organization headquartered in Norwich, GB. It trades on NYSE under ticker HOTH. Primary therapeutic focus areas include Skin Toxicities Associated with Epidermal Growth Factor Receptor I
Norwich, GB HQ
12 Employees
Public company Type
HOTH · NYSE Ticker
Company details
- Status
- Public
- HQ
- Norwich, GB
- Employees
- 12
- Programs
- 3
- Drugs
- 4
- Patents
- 1
CLEER-001
Phase 2 · small molecule · Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
CLEER-001 for Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors is a Phase 2 program (small_molecule) at Hoth Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CLEER-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hoth Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
- Status
- active
- Trials
- 1